CD8A and breast carcinoma: Furthermore, recent studies in animal models revealed that SSRIs significantly enhance CD8+ T‐cell function in various tumor models, including melanoma, breast cancer, prostate cancer, and colorectal cancer models, leading to greater than 50% tumor growth inhibition.